The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man
- 1 September 1989
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 38 (17) , 2795-2799
- https://doi.org/10.1016/0006-2952(89)90433-4
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- In vitro studies of induction and inhibition of drug oxidation in manPharmacology & Therapeutics, 1987
- Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat PolymorphismDNA, 1987
- Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1986
- Bufuralol 1'-hydroxylase activity of the ratBiochemical Pharmacology, 1986
- Attempts to phenotype human liver samples in vitro for debrisoquine 4‐ hydroxylase activity.British Journal of Clinical Pharmacology, 1985
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractionsBiochemical Pharmacology, 1981
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977